Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Anti-VEGF eye injection for macular degeneration and diabetic eye disease. | Sight-saving eye injection for wet macular degeneration. |
| Body system | Eyes | Eyes |
| Drug class | Anti-VEGF injections | Anti-VEGF injections |
| Supply | Prescription onlyWHO essential medicine | Prescription only |
| Main uses | Wet age-related macular degeneration, Diabetic macular oedema, Retinal vein occlusion, Myopic choroidal neovascularisation | Wet age-related macular degeneration, Diabetic macular oedema, Retinal vein occlusion |
| How it works | Stops abnormal blood vessels leaking in the retina. | Blocks the signal that grows leaky vessels at the back of the eye. |
| Starts working | Weeks | — |
| Half-life | About 9 days (vitreous) | — |
| Typical adult dose | 0.5 mg injected into the eye monthly, then as needed or at extended intervals. | 2 mg monthly for 3 months, then every 8–16 weeks (8 mg high-dose can extend further). |
| Forms | Intravitreal injection | Intravitreal injection |
| Common side effects | Eye pain, Floaters, Redness, Raised eye pressure | Eye redness, Floaters, Eye pain |
| Serious side effects | Endophthalmitis (serious eye infection), Retinal detachment, Arterial clots (rare) | Eye infection (endophthalmitis), Retinal detachment, Raised eye pressure |
| Don't take if | Active eye infection; Active intraocular inflammation | — |
| Alcohol | Usually no problem in moderation. No specific interaction. | — |
| Pregnancy | Use with cautionLimited data; specialist decision. | Usually avoidedNot recommended. |
| Breastfeeding | Use with cautionLimited data. | — |
| In use since | — | 2011 |
| Brand names | United States: Lucentis, Byooviz, CimerliUnited Kingdom: Lucentis, RanivisioIndia: Lucentis, Razumab, Ranibizumab biosimilars | United States: Eylea, Eylea HDUnited Kingdom: EyleaIndia: Eylea |
| Legal status | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H | — |
| ATC code | S01LA04 | S01LA05 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker